Kidney International Supplements最新文献

{"title":"Capacity for the management of kidney failure in the International Society of Nephrology Newly Independent States and Russia region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA)","authors":"Larisa Prikhodina ,&nbsp;Kirill Komissarov ,&nbsp;Nikolay Bulanov ,&nbsp;Silvia Arruebo ,&nbsp;Aminu K. Bello ,&nbsp;Fergus J. Caskey ,&nbsp;Sandrine Damster ,&nbsp;Jo-Ann Donner ,&nbsp;Vivekanand Jha ,&nbsp;David W. Johnson ,&nbsp;Adeera Levin ,&nbsp;Charu Malik ,&nbsp;Masaomi Nangaku ,&nbsp;Ikechi G. Okpechi ,&nbsp;Marcello Tonelli ,&nbsp;Feng Ye ,&nbsp;Abduzhappar Gaipov","doi":"10.1016/j.kisu.2024.01.005","DOIUrl":"https://doi.org/10.1016/j.kisu.2024.01.005","url":null,"abstract":"<div><p>The International Society of Nephrology Global Kidney Health Atlas (ISN-GKHA) was established to aid understanding of the status and capacity of countries to provide optimal kidney care worldwide. This report presents the current characteristics of kidney care in the ISN Newly Independent States (NIS) and Russia region. Although the median prevalence of chronic kidney disease (CKD) was higher (11.4%) than the global median (9.5%), the median CKD-related death rate (1.4%) and prevalence of treated kidney failure (KF) in the region (411 per million population [pmp]) were lower than they are globally (2.5% and 822.8 pmp, respectively). Capacity to provide an adequate frequency of hemodialysis (HD) and kidney transplantation services is present in all the countries (100%). In spite of significant economic advancement, the region has critical shortages of nephrologists, dietitians, transplant coordinators, social workers, palliative care physicians, and kidney supportive care nurses. Home HD remains unavailable in any country in the region. Although national registries for dialysis and kidney transplantation are available in most of the countries across the ISN NIS and Russia region, few registries exist for nondialysis CKD and acute kidney injury. Although a national strategy for improving care for CKD patients is presented in more than half of the countries, no country in the region had a CKD-specific policy. Strategies that incorporate workforce training, planning, and development for all KF caregivers could help ensure sustainable kidney care delivery in the ISN NIS and Russia region.</p></div>","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"13 1","pages":"Pages 71-82"},"PeriodicalIF":5.5,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140537015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Capacity for the management of kidney failure in the International Society of Nephrology North and East Asia region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA)","authors":"Winston Wing-Shing Fung ,&nbsp;Hyeong Cheon Park ,&nbsp;Yosuke Hirakawa ,&nbsp;Silvia Arruebo ,&nbsp;Aminu K. Bello ,&nbsp;Fergus J. Caskey ,&nbsp;Sandrine Damster ,&nbsp;Jo-Ann Donner ,&nbsp;Vivekanand Jha ,&nbsp;David W. Johnson ,&nbsp;Adeera Levin ,&nbsp;Charu Malik ,&nbsp;Masaomi Nangaku ,&nbsp;Ikechi G. Okpechi ,&nbsp;Marcello Tonelli ,&nbsp;Seiji Ueda ,&nbsp;Feng Ye ,&nbsp;Yusuke Suzuki ,&nbsp;Angela Yee-Moon Wang ,&nbsp;Lili Zhou","doi":"10.1016/j.kisu.2024.02.001","DOIUrl":"https://doi.org/10.1016/j.kisu.2024.02.001","url":null,"abstract":"<div><p>Globally, there remain significant disparities in the capacity and quality of kidney care, as evidenced by the third edition of the International Society of Nephrology Global Kidney Health Atlas (ISN-GKHA). In the ISN North and East Asia region, the chronic kidney disease (CKD) burden varied widely; Taiwan had the heaviest burden of treated kidney failure (3679 per million population [pmp]) followed by Japan and South Korea. Except in Hong Kong, hemodialysis (HD) was the main dialysis modality for all other countries in the region and was much higher than the global median prevalence. Kidney transplantation services were generally available in the region, but the prevalence was much lower than that of dialysis. Most countries had public funding for kidney replacement therapy (KRT). The median prevalence of nephrologists was 28.7 pmp, higher than that of any other ISN region, with variation across countries. Home HD was available in only 17% of the countries, whereas conservative kidney management was available in 50%. All countries had official registries for dialysis and transplantation; however, only China and Japan had CKD registries. Advocacy groups for CKD, kidney failure, and KRT were uncommon throughout the region. Overall, all countries in the region had capacity for KRT, albeit with some shortages in their kidney care workforce. These data are useful for stakeholders to address gaps in kidney care and to reduce workforce shortages through increased use of multidisciplinary teams and telemedicine, policy changes to promote prevention and treatment of kidney failure, and increased advocacy for kidney disease in the region.</p></div>","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"13 1","pages":"Pages 97-109"},"PeriodicalIF":5.5,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140537074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Capacity for the management of kidney failure in the International Society of Nephrology Oceania and South East Asia (OSEA) region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA)","authors":"Anna Francis ,&nbsp;Marina Wainstein ,&nbsp;Georgina Irish ,&nbsp;Muhammad Iqbal Abdul Hafidz ,&nbsp;Titi Chen ,&nbsp;Yeoungjee Cho ,&nbsp;Htay Htay ,&nbsp;Talerngsak Kanjanabuch ,&nbsp;Rowena Lalji ,&nbsp;Brendon L. Neuen ,&nbsp;Emily See ,&nbsp;Anim Shah ,&nbsp;Brendan Smyth ,&nbsp;Somkanya Tungsanga ,&nbsp;Andrea Viecelli ,&nbsp;Emily K. Yeung ,&nbsp;Silvia Arruebo ,&nbsp;Aminu K. Bello ,&nbsp;Fergus J. Caskey ,&nbsp;Sandrine Damster ,&nbsp;Deenaz Zaidi","doi":"10.1016/j.kisu.2024.01.004","DOIUrl":"https://doi.org/10.1016/j.kisu.2024.01.004","url":null,"abstract":"<div><p>The International Society of Nephrology (ISN) region of Oceania and South East Asia (OSEA) is a mix of high- and low-income countries, with diversity in population demographics and densities. Three iterations of the ISN-Global Kidney Health Atlas (GKHA) have been conducted, aiming to deliver in-depth assessments of global kidney care across the spectrum from early detection of CKD to treatment of kidney failure. This paper reports the findings of the latest ISN-GKHA in relation to kidney-care capacity in the OSEA region. Among the 30 countries and territories in OSEA, 19 (63%) participated in the ISN-GKHA, representing over 97% of the region’s population. The overall prevalence of treated kidney failure in the OSEA region was 1203 per million population (pmp), 45% higher than the global median of 823 pmp. In contrast, kidney replacement therapy (KRT) in the OSEA region was less available than the global median (chronic hemodialysis, 89% OSEA region vs. 98% globally; peritoneal dialysis, 72% vs. 79%; kidney transplantation, 61% vs. 70%). Only 56% of countries could provide access to dialysis to at least half of people with incident kidney failure, lower than the global median of 74% of countries with available dialysis services. Inequalities in access to KRT were present across the OSEA region, with widespread availability and low out-of-pocket costs in high-income countries and limited availability, often coupled with large out-of-pocket costs, in middle- and low-income countries. Workforce limitations were observed across the OSEA region, especially in lower-middle–income countries. Extensive collaborative work within the OSEA region and globally will help close the noted gaps in kidney-care provision.</p></div>","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"13 1","pages":"Pages 110-122"},"PeriodicalIF":5.5,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140537173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Capacity for the management of kidney failure in the International Society of Nephrology Africa region: report from the 2023 ISN Global Kidney Atlas (ISN-GKHA)","authors":"Elliot Koranteng Tannor ,&nbsp;Bianca Davidson ,&nbsp;Yannick Nlandu ,&nbsp;Peace Bagasha ,&nbsp;Workagegnehu Hailu Bilchut ,&nbsp;M. Razeen Davids ,&nbsp;Hassane M. Diongole ,&nbsp;Udeme E. Ekrikpo ,&nbsp;Ehab O.A. Hafiz ,&nbsp;Kwaifa Salihu Ibrahim ,&nbsp;Robert Kalyesubula ,&nbsp;Aisha M. Nalado ,&nbsp;Timothy O. Olanrewaju ,&nbsp;Ugochi Chika Onu ,&nbsp;Nikhil Pereira-Kamath ,&nbsp;Aminu Muhammad Sakajiki ,&nbsp;Mohamed Salah ,&nbsp;Lloyd Vincent ,&nbsp;Silvia Arruebo ,&nbsp;Aminu K. Bello ,&nbsp;Deenaz Zaidi","doi":"10.1016/j.kisu.2024.01.002","DOIUrl":"https://doi.org/10.1016/j.kisu.2024.01.002","url":null,"abstract":"<div><p>The burden of chronic kidney disease and associated risk of kidney failure are increasing in Africa. The management of people with chronic kidney disease is fraught with numerous challenges because of limitations in health systems and infrastructures for care delivery. From the third iteration of the International Society of Nephrology Global Kidney Health Atlas, we describe the status of kidney care in the ISN Africa region using the World Health Organization building blocks for health systems. We identified limited government health spending, which in turn led to increased out-of-pocket costs for people with kidney disease at the point of service delivery. The health care workforce across Africa was suboptimal and further challenged by the exodus of trained health care workers out of the continent. Medical products, technologies, and services for the management of people with nondialysis chronic kidney disease and for kidney replacement therapy were scarce due to limitations in health infrastructure, which was inequitably distributed. There were few kidney registries and advocacy groups championing kidney disease management in Africa compared with the rest of the world. Strategies for ensuring improved kidney care in Africa include focusing on chronic kidney disease prevention and early detection, improving the effectiveness of the available health care workforce (e.g., multidisciplinary teams, task substitution, and telemedicine), augmenting kidney care financing, providing quality, up-to-date health information data, and improving the accessibility, affordability, and delivery of quality treatment (kidney replacement therapy or conservative kidney management) for all people living with kidney failure.</p></div>","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"13 1","pages":"Pages 12-28"},"PeriodicalIF":5.5,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140537180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of mineralocorticoid receptor activation in kidney inflammation and fibrosis.","authors":"J. Luther, A. Fogo","doi":"10.1016/j.kisu.2021.11.006","DOIUrl":"https://doi.org/10.1016/j.kisu.2021.11.006","url":null,"abstract":"","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"9 1","pages":"63-68"},"PeriodicalIF":5.5,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78693597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Considerations for the future: current and future treatment paradigms with mineralocorticoid receptor antagonists-unmet needs and underserved patient cohorts.","authors":"Murray Epstein","doi":"10.1016/j.kisu.2021.11.008","DOIUrl":"https://doi.org/10.1016/j.kisu.2021.11.008","url":null,"abstract":"","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"19 1","pages":"69-75"},"PeriodicalIF":5.5,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76208348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical perspective—evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes","authors":"Peter Rossing","doi":"10.1016/j.kisu.2021.11.005","DOIUrl":"https://doi.org/10.1016/j.kisu.2021.11.005","url":null,"abstract":"<div><p>Chronic kidney disease (CKD) in type 2 diabetes is a large and growing problem leading to end-stage kidney disease, atherosclerotic cardiovascular disease, and heart failure (HF). Aldosterone is a key risk factor in promoting inflammation and fibrosis, which causes cardiorenal failure. Treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers does not prevent overactivation of the mineralocorticoid receptor. Therapeutic options and challenges with blocking MR overactivation by aldosterone are reviewed herein. Whereas classic steroidal mineralocorticoid receptor antagonists (MRAs) reduced albuminuria in short-term studies of diabetic and nondiabetic CKD, long-term studies evaluating hard endpoints such as loss of kidney function were not conducted in CKD because of side effects (primarily hyperkalemia). Novel nonsteroidal MRAs reduce proteinuria and markers of HF, with lower risk of hyperkalemia and without renal impairment, in comparison to steroidal MRAs. Furthermore, recent clinical trials have demonstrated the efficacy of the novel, selective, nonsteroidal MRA finerenone to delay progression of kidney and cardiovascular disease, including HF, in patients with CKD and type 2 diabetes. Concomitantly, the safety profile of finerenone is good, with few patients discontinuing treatment because of hyperkalemia, even among study participants with a low estimated glomerular filtration rate (&gt;25 ml/min per 1.73 m²). Novel nonsteroidal MRAs such as finerenone hold the potential to be an attractive addition to the treatment paradigm in the management of patients with CKD and type 2 diabetes, targeting the unmet need of managing increased inflammation and fibrosis attributable to MR overactivation.</p></div>","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"12 1","pages":"Pages 27-35"},"PeriodicalIF":5.5,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S215717162100068X/pdfft?md5=2da6385c1c2a6b203bac6e2211daf953&pid=1-s2.0-S215717162100068X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72089520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The renin–angiotensin system biomolecular cascade: a 2022 update of newer insights and concepts","authors":"Carlos M. Ferrario ,&nbsp;Leanne Groban ,&nbsp;Hao Wang ,&nbsp;Xuming Sun ,&nbsp;Jessica L. VonCannon ,&nbsp;Kendra N. Wright ,&nbsp;Sarfaraz Ahmad","doi":"10.1016/j.kisu.2021.11.002","DOIUrl":"https://doi.org/10.1016/j.kisu.2021.11.002","url":null,"abstract":"<div><p>A large body of evidence implicates the renin–angiotensin system in the pathogenesis of cardiovascular disease. However, not everyone understands that the magnitude of the risk reduction achieved in clinical trials with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers is only a fraction of the residual risk for cardiovascular events and death. This paper addresses limitations of current therapeutic approaches based on renin–angiotensin system blockade for hypertension and cardiovascular disease by illustrating the complex biochemical physiology and mechanism of classical and alternate angiotensin peptide formation. Emerging evidence of alternate mechanisms that bypass both renin and angiotensin-converting enzyme to produce the angiotensins in tissues and cells is not currently universally recognized. Currently available treatment would benefit from further insights to help fully meet the aims of patient care, and the challenge is to delve more deeply into the renin–angiotensin system cascade, with the aim of enhancing therapeutics for renin–angiotensin system inhibition. This article provides a reappraisal of the renin–angiotensin–aldosterone cascade, highlighting newly elucidated intermediary components and interplay, and their consequent implications and relevance for understanding the long-term contribution of angiotensin II in cardiovascular diseases and their therapy.</p></div>","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"12 1","pages":"Pages 36-47"},"PeriodicalIF":5.5,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2157171621000654/pdfft?md5=1c24d37f86c54dea0faad5deb66f3045&pid=1-s2.0-S2157171621000654-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72089522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology of chronic kidney disease: an update 2022","authors":"Csaba P. Kovesdy","doi":"10.1016/j.kisu.2021.11.003","DOIUrl":"10.1016/j.kisu.2021.11.003","url":null,"abstract":"<div><p>Chronic kidney disease is a progressive condition that affects &gt;10% of the general population worldwide, amounting to &gt;800 million individuals. Chronic kidney disease is more prevalent in older individuals, women, racial minorities, and in people experiencing diabetes mellitus and hypertension. Chronic kidney disease represents an especially large burden in low- and middle-income countries, which are least equipped to deal with its consequences. Chronic kidney disease has emerged as one of the leading causes of mortality worldwide, and it is one of a small number of non-communicable diseases that have shown an increase in associated deaths over the past 2 decades. The high number of affected individuals and the significant adverse impact of chronic kidney disease should prompt enhanced efforts for better prevention and treatment.</p></div>","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"12 1","pages":"Pages 7-11"},"PeriodicalIF":5.5,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9073222/pdf/main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10248066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nonepithelial mineralocorticoid receptor activation as a determinant of kidney disease.","authors":"Toshifumi Nakamura, S. Girerd, F. Jaisser, J. Barrera-Chimal","doi":"10.1016/j.kisu.2021.11.004","DOIUrl":"https://doi.org/10.1016/j.kisu.2021.11.004","url":null,"abstract":"","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"91 1","pages":"12-18"},"PeriodicalIF":5.5,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74199336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}